Article
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.
PloS one - 1 Jan 2012
Scherrer Alexandra U, Ledergerber Bruno, von Wyl Viktor, Böni Jürg, Yerly Sabine, Klimkait Thomas, Cellerai Cristina, Furrer Hansjakob, Calmy Alexandra, Cavassini Matthias, Elzi Luigia, Vernazza Pietro L, Bernasconi Enos, Günthard Huldrych F
Abstract excerpt
BACKGROUND: Minor protease inhibitor (PI) mutations often exist as polymorphisms in HIV-1 sequences from treatment-naïve patients. Previous studies showed that their presence impairs the antiretroviral treatment (ART) response. Evaluating these findings in a larger cohort is essential. METHODS: To study the impact of minor PI mutations on time to viral suppression and time to virological failure, we included...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
